MK-1045

Phase 2Biologic

Merck & Co.

MK-1045 is one of 156 biologic programs targeting Lymphoma, Non-Hodgkin. It is currently in Phase 2.

Indications

Total Trials

Active Trials

155

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoma, Non-HodgkinRecruiting

Systemic Lupus ErythematosusRecruiting

Follicular LymphomaRecruiting

Refractory B-Cell Non-Hodgkin LymphomaRecruiting

B-Cell Acute Lymphoblastic LeukemiaRecruiting

Acute Lymphoblastic LeukemiaRecruiting

Chronic Lymphocytic LeukaemiaNot yet recruiting

Lymphoma, Non-HodgkinPreclinical

Recruiting

Systemic Lupus ErythematosusPhase 1

Recruiting

Follicular LymphomaPreclinical

Recruiting

Refractory B-Cell Non-Hodgkin LymphomaPhase 1

Recruiting

B-Cell Acute Lymphoblastic LeukemiaPreclinical

Recruiting

Acute Lymphoblastic LeukemiaPreclinical

Recruiting

Chronic Lymphocytic LeukaemiaPhase 2

Not yet recruiting

Competition

Competitive Landscape

163 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

75 2

Adriamycin

Pfizer

Phase 3

40 3

Oncaspar

SServier

Phase 3

48 4

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

40 5

Elspar

DDutch Childhood Oncology Group

Phase 3

45 6

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

43 7

Fludara

Sanofi

Phase 3

15 8

Medrol

Pfizer

Phase 3

12 9

Iclusig

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Acute Lymphoblastic Leukemia

NCT05579132

Q1 2029

Phase 1Recruiting

Refractory B-Cell Non-Hodgkin Lymphoma

NCT06189391

Q3 2029

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT07363590

Q2 2031

PreclinicalRecruiting

Lymphoma, Non-Hodgkin

NCT07519772

Clinical

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07570173·340 enrolled

Follicular Lymphoma1 trial

A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07634471·960 enrolled

Lymphoma, Non-Hodgkin1 trial

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07519772·280 enrolled

Systemic Lupus Erythematosus1 trial

A Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1045 in Participants With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07363590·21 enrolled

Chronic Lymphocytic Leukaemia1 trial

A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies

Not yet recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07709000·60 enrolled

2 more indications

Acute Lymphoblastic Leukemia1 trial

An Open-label, Multi-center Phase Ib/II Study of MK-1045 (CN201) in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia

Recruiting·MMSD R&D (China) Co., Ltd.·Preclinical·NCT05579132·203 enrolled

Refractory B-Cell Non-Hodgkin Lymphoma1 trial

An Open-Label, Dose Escalation Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-1045 (CN201) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting·MMSD R&D (China) Co., Ltd.·Phase 1·NCT06189391·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for MK-1045. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK-1045 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK-1045. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

MK-1045

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Q3 2029

Q2 2031

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

Follicular Lymphoma1 trial

Lymphoma, Non-Hodgkin1 trial

Systemic Lupus Erythematosus1 trial

Chronic Lymphocytic Leukaemia1 trial

Acute Lymphoblastic Leukemia1 trial

Refractory B-Cell Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News